Literature DB >> 19937690

High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy.

Xiaofeng Fan1, Qing Mao, Donghui Zhou, Yang Lu, Jianwei Xing, Yanjuan Xu, Stuart C Ray, Adrian M Di Bisceglie.   

Abstract

UNLABELLED: Differential response patterns to optimal antiviral therapy, peginterferon alpha plus ribavirin, are well documented in patients with chronic hepatitis C virus (HCV) infection. Among many factors that may affect therapeutic efficiency, HCV quasispecies (QS) characteristics have been a major focus of previous studies, yielding conflicting results. To obtain a comprehensive understanding of the role of HCV QS in antiviral therapy, we performed the largest-ever HCV QS analysis in 153 patients infected with HCV genotype 1 strains. A total of 4,314 viral clones spanning hypervarible region 1 were produced from these patients during the first 12 weeks of therapy, followed by detailed genetic analyses. Our data show an exponential distribution pattern of intrapatient QS diversity in this study population in which most patients (63%) had small QS diversity with genetic distance (d) less than 0.2. The group of patients with genetic distance located in the decay region (d>0.53) had a significantly higher early virologic response (EVR) rate (89.5%), which contributed substantially to the overall association between EVR and increased baseline QS diversity. In addition, EVR was linked to a clustered evolutionary pattern in terms of QS dynamic changes.
CONCLUSION: EVR is associated with elevated HCV QS diversity and complexity, especially in patients with significantly higher HCV genetic heterogeneity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19937690      PMCID: PMC2911951          DOI: 10.1002/hep.23290

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  41 in total

1.  Position and degree of mismatches and the mobility of DNA heteroduplexes.

Authors:  D A Upchurch; R Shankarappa; J I Mullins
Journal:  Nucleic Acids Res       Date:  2000-06-15       Impact factor: 16.971

2.  Dengue type 3 virus in plasma is a population of closely related genomes: quasispecies.

Authors:  Wei-Kung Wang; Su-Ru Lin; Chao-Min Lee; Chwan-Chuen King; Shan-Chwen Chang
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin.

Authors:  Isabella Abbate; Oreste Lo Iacono; Rosa Di Stefano; Giuseppina Cappiello; Enrico Girardi; Roberta Longo; Donatella Ferraro; Giorgio Antonucci; Vito Di Marco; Mariacarmela Solmone; Antonio Craxì; Giuseppe Ippolito; Maria R Capobianchi
Journal:  J Hepatol       Date:  2004-05       Impact factor: 25.083

Review 4.  What is a quasispecies?

Authors:  C K Biebricher; M Eigen
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

5.  Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients.

Authors:  Y Kanazawa; N Hayashi; E Mita; T Li; H Hagiwara; A Kasahara; H Fusamoto; T Kamada
Journal:  Hepatology       Date:  1994-11       Impact factor: 17.425

6.  HIV quasispecies and resampling.

Authors:  S L Liu; A G Rodrigo; R Shankarappa; G H Learn; L Hsu; O Davidov; L P Zhao; J I Mullins
Journal:  Science       Date:  1996-07-26       Impact factor: 47.728

Review 7.  Phylogenetic analysis in molecular evolutionary genetics.

Authors:  M Nei
Journal:  Annu Rev Genet       Date:  1996       Impact factor: 16.830

8.  Sampling and repeatability in the evaluation of hepatitis C virus genetic variability.

Authors:  Manuela Torres-Puente; M Alma Bracho; Nuria Jiménez; Inmaculada García-Robles; Andrés Moya; Fernando González-Candelas
Journal:  J Gen Virol       Date:  2003-09       Impact factor: 3.891

9.  Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.

Authors:  Chihiro Morishima; Stephen J Polyak; Ranjit Ray; Michael C Doherty; Adrian M Di Bisceglie; Peter F Malet; Herbert L Bonkovsky; Daniel G Sullivan; David R Gretch; Alan L Rothman; Margaret James Koziel; Karen L Lindsay
Journal:  J Infect Dis       Date:  2006-02-22       Impact factor: 5.226

10.  Characterization of the 5' noncoding and structural region of the hepatitis C virus genome from patients with non-A, non-B hepatitis responding differently to interferon treatment.

Authors:  T Nakazawa; N Kato; S Ohkoshi; A Shibuya; K Shimotohno
Journal:  J Hepatol       Date:  1994-05       Impact factor: 25.083

View more
  17 in total

1.  Mutagen resistance and mutation restriction of St. Louis encephalitis virus.

Authors:  Sara B Griesemer; Laura D Kramer; Greta A Van Slyke; Janice D Pata; David W Gohara; Craig E Cameron; Alexander T Ciota
Journal:  J Gen Virol       Date:  2017-02       Impact factor: 3.891

2.  Clinical implications of evolutionary patterns of homologous, full-length hepatitis B virus quasispecies in different hosts after perinatal infection.

Authors:  Feng Liu; De-Min Yu; Su-Yuan Huang; Jia-Lun Yu; Dong-Hua Zhang; Qi-Ming Gong; Xin-Xin Zhang
Journal:  J Clin Microbiol       Date:  2014-02-26       Impact factor: 5.948

3.  Comprehensive cloning of patient-derived 9022-bp amplicons of hepatitis C virus.

Authors:  Yang Lu; Yanjuan Xu; Adrian M Di Bisceglie; Xiaofeng Fan
Journal:  J Virol Methods       Date:  2013-04-17       Impact factor: 2.014

4.  Evidence for deleterious hepatitis C virus quasispecies mutation loads that differentiate the response patterns in IFN-based antiviral therapy.

Authors:  Yi Ren; Weihua Wang; Xiaoan Zhang; Yanjuan Xu; Adrian M Di Bisceglie; Xiaofeng Fan
Journal:  J Gen Virol       Date:  2015-11-18       Impact factor: 3.891

5.  Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.

Authors:  John E Tavis; Maureen J Donlin; Rajeev Aurora; Xiaofeng Fan; Adrian M Di Bisceglie
Journal:  Genome Med       Date:  2011-02-08       Impact factor: 11.117

6.  Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

Authors:  Severine Margeridon-Thermet; Robert W Shafer
Journal:  Viruses       Date:  2010-12-01       Impact factor: 5.048

7.  New details of HCV NS3/4A proteinase functionality revealed by a high-throughput cleavage assay.

Authors:  Sergey A Shiryaev; Elliot R Thomsen; Piotr Cieplak; Eugene Chudin; Anton V Cheltsov; Mark S Chee; Igor A Kozlov; Alex Y Strongin
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

8.  Probing of exosites leads to novel inhibitor scaffolds of HCV NS3/4A proteinase.

Authors:  Sergey A Shiryaev; Anton V Cheltsov; Alex Y Strongin
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

Review 9.  Interaction Between the Neglected Tropical Disease Human Schistosomiasis and HCV Infection in Egypt: a Puzzling Relationship.

Authors:  Mahmoud M Bahgat
Journal:  J Clin Transl Hepatol       Date:  2014-06-15

10.  Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study.

Authors:  Luísa Hoffmann; Juliene Antonio Ramos; Elizabeth Valentin de Souza; Ana Lucia de Araújo Ramos; Cristiane Alves Villela-Nogueira; Turán Péter Urményi; Amilcar Tanuri; Edson Rondinelli; Rosane Silva
Journal:  Virol J       Date:  2013-02-14       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.